Serviks Kanser Hücre Hattında Timokinonun Sisplatin Sitotoksisitesine Etkilerinin İncelenmesi
xmlui.mirage2.itemSummaryView.MetaDataShow full item record
Thymoquinone, derived from the volatile oil of Nigella sativa L. seed known as black seed “çörek otu” in Turkey, is a monoterpene molecule and a bioactive compound. Along with being consumed as food for centuries, thymoquinone has been suggested to have a wide range of protection from anticancer effect to antiallergic effect due to mainly its antioxidant properties and especially its effect on glutathione mechanism. Cisplatin, a platinum-based anticancer agent, as been over, has been used for many years in the therapy of the solid tumours such as cervix, testis, prostate, bladder, lung cancers, and its mechanism is well known. The use of plant extracts in combination with chemotherapeutic drugs has been investigated in order to reduce the side effects of the drugs used in the chemotherapy and to increase their effects on the body. In this thesis study, the cytotoxic effects of the use of thymoquinone, which is known to be significant biological effects and of which the importance has been increasingly in recent studies, were investigated in combination with anticancer drug cisplatin in the cervical cancer cells (HeLa) using MTT method. After determination of the cytotoxicity profiles of cisplatin and thymoquinone at different times, the effects of thymoquinone in a wide dose range on the IC50 values of cisplatin were investigated. In HeLa cells, for 24 h and 48 h incubations, IC50 values of thymoquinone were found to be 143.7 μM and 67.5 μM, respectively and IC50 values of cisplatin were found to be 20.3 μM and 12.9 μM, respectively. Thymoquinone at the concentration range of 7.8-250 μM for 24 h incubation and 15.6-250 μM for 48 h incubation, has been shown to statistically significant decrease the IC50 values cisplatin in a dose-dependent in HeLa cells. In conclusion, our findings indicate that thymoquinone may increased the cytotoxicity of cisplatin in HeLa cells, and therefore thymoquinone may increase the anticancer effect of cisplatin; however to confirm these effects and to determine its interactions with anticancer drugs, the advanced in vitro and in vivo studies are needed.